- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00311701
Chart Review of Antivirals for Influenza in Infants
12. mai 2011 oppdatert av: National Institute of Allergy and Infectious Diseases (NIAID)
A Retrospective Chart Review to Assess the Safety of Oseltamivir (Tamiflu®) Compared to Alternate Antiviral Therapy (Amantadine or Rimantadine) Administered to Children Less Than 12 Months of Age With Diagnosed or Suspected Influenza (CASG 113)
This retrospective study conducted in Canada and the US involves a chart review to assess the safety of oseltamivir (Tamiflu®) compared to alternate antiviral therapy, amantidine or rimantidine, administered to children less than 12 months of age with diagnosed or suspected influenza.
The objectives are to describe the frequency of neurological and all other adverse events possibly related to administration of these antivirals in these infants.
Investigators will also compare frequency of adverse events at various doses of oseltamivir in these children.
Critical endpoints to be collected include frequency and severity of adverse events, particularly those relating to central nervous system complications.
A sub-investigator will travel to each of the participating sites to collect data related to each infant's health prior to becoming ill, health status at time of influenza diagnosis, dosing regimen, reported neurological events post-dosing, and all reported adverse events post-dosing.
Studieoversikt
Status
Fullført
Forhold
Detaljert beskrivelse
The study is a retrospective review of charts of children less than 12 months of age that were diagnosed with influenza and treated with oseltamivir.
The chart review will focus on assessment of neurological and other adverse events that may have been related to the administration of oseltamivir.
A control population will consist of children less than 12 months treated with either rimantadine or amantadine.
The administration of oseltamivir to children at high risk (i.e.
immunocompromised hosts) less than 12 months old with influenza is frequently considered in medical practice despite the findings of neurotoxicity in a juvenile rat study.
Since oseltamivir is the only active treatment against H5N1 influenza strains, it is imperative to understand the ramifications of its potential widespread use in very young infants in the event of an outbreak.
This study is designed to gather documented evidence by which the circumstances of use and defined outcomes can be described.
Patient selection will be made by review of hospital inpatient medical records, emergency room medical records and/or pharmacy records to identify patients less than 1 yr old dosed with oseltamivir suspension.
Redacting the charts will be done in a manner that will obscure personal health information (individual identifiers) without obscuring the necessary clinical data.
A separate research data collection form will be prepared on which critical information can be transcribed that would subsequently be available for analysis.
Critical information to be captured at the time of initiating oseltamivir treatment includes: age, birth history, gender, underlying medical conditions, presenting influenza symptoms, if done, type of flu test and dose regime.
Critical endpoints to be collected will include the frequency and severity of adverse events, particularly those relating to central nervous system complications.
Studietype
Observasjonsmessig
Registrering
200
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233-0011
- University of Alabama at Birmingham
-
-
Arkansas
-
Pulaski, Arkansas, Forente stater, 72202
- Arkansas Children's Hospital
-
-
California
-
Orange, California, Forente stater, 92868
- Children's Hospital of Orange County
-
San Diego, California, Forente stater, 92123
- Children's Hospital and Health Center
-
-
Colorado
-
Denver, Colorado, Forente stater, 80218
- University of Colorado
-
-
Missouri
-
Saint Louis, Missouri, Forente stater, 63110
- Washington University in St. Louis
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68198-2162
- Creighton University
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44109
- MetroHealth Medical Center
-
-
Oregon
-
Portland, Oregon, Forente stater, 97201-3098
- Oregon Health Sciences University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Children's Hospital of Philadelphia
-
-
Texas
-
Dallas, Texas, Forente stater, 75390-9063
- The University of Texas Southwestern Medical Center
-
Fort Worth, Texas, Forente stater, 76104
- Cook Children's Medical Center
-
San Antonio, Texas, Forente stater, 78229-3900
- The University of Texas Health Science Center
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84132
- University of Utah
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Seattle Children's Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Ikke eldre enn 11 måneder (Barn)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Male or female study participants less than 12 months of age
- Suspected or laboratory diagnosis of influenza
- Treated with oseltamivir, rimantadine or amantadine
Exclusion Criteria:
None listed
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. november 2005
Studiet fullført
1. desember 2006
Datoer for studieregistrering
Først innsendt
5. april 2006
Først innsendt som oppfylte QC-kriteriene
5. april 2006
Først lagt ut (Anslag)
6. april 2006
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
13. mai 2011
Siste oppdatering sendt inn som oppfylte QC-kriteriene
12. mai 2011
Sist bekreftet
1. oktober 2007
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 05-0111
- N01AI30025C
- CASG 113
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .